EVERSUN: A PHASE 2 TRIAL OF EVEROLIMUS ALTERNATING WITH SUNITINIB AS FIRST-LINE THERAPY FOR ADVANCED RENAL CELL CARCINOMA (ANZUP TRIAL 0901)

被引：0
|
作者：
Davis, I. D. [1 ]
Long, A. [2 ,13 ]
Martin, A. [2 ,13 ]
Espinoza, D. [2 ,13 ]
Yip, S. [2 ,13 ]
Thompson, J. F. [2 ]
Kichenadasse, G. [3 ]
Harrison, M. [4 ]
Lowenthal, R. M. [6 ]
Pavlakis, N. [5 ]
Azad, A. [7 ]
Kannourakis, G. [8 ]
Steer, C. [9 ]
Goldstein, D. [10 ]
Shapiro, J. [11 ]
Stockler, M. R. [2 ,4 ,12 ,13 ]
机构：
[1] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic 3004, Australia
[2] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia
[3] Flinders Med Ctr, Adelaide, SA, Australia
[4] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[5] Univ Sydney, Royal N Shore Hosp, Sydney, NSW 2006, Australia
[6] Royal Hobart Hosp, Hobart, Tas, Australia
[7] Austin Hlth, Melbourne, Vic, Australia
[8] Ballarat Oncol & Haematol Serv, Ballarat, Vic, Australia
[9] Border Med Oncol, Wodonga, Vic, Australia
[10] Univ New S Wales, Prince Wales Hosp, Sydney, NSW, Australia
[11] Cabrini Inst, Melbourne, Vic, Australia
[12] Concord Canc Ctr, Concord, NSW, Australia
[13] Sydney Catalyst Translat Canc Res Ctr, Sydney, NSW, Australia
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/j.ejca.2014.03.255
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P0211
引用
收藏
页码：E68 / E69
页数：2
相关论文
共 50 条
  • [1] EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901)
    Davis, Ian D.
    Long, Anne
    Martin, Andrew
    Espinoza, David
    Yip, Sonia
    Kichenadasse, Ganessan
    Thompson, Jennifer F.
    Harrison, Michelle L.
    Lowenthal, Raymond M.
    Pavlakis, Nick
    Azad, Arun
    Kannourakis, George
    Steer, Christopher
    Goldstein, David
    Shapiro, Jeremy David
    Stockler, Martin R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [2] EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) (ANZUP trial 0901).
    Davis, Ian D.
    Gebski, Val
    Chatfield, Mark D.
    Grimison, Peter S.
    Kannourakis, George
    Boland, Amy L.
    Thompson, Jennifer
    Stockler, Martin R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] CIRCULATING BIOMARKERS AND OUTCOMES IN A PHASE 2 TRIAL OF FIRST-LINE EVEROLIMUS ALTERNATING WITH SUNITINIB FOR ADVANCED RENAL CELL CARCINOMA (ANZUP 0901-THE EVERSUN TRIAL)
    Yip, S.
    Pavlakis, N.
    Harvie, R.
    Martin, A.
    Hudson, A.
    Thompson, J. F.
    Long, A.
    Steer, C.
    Stockler, M. R.
    Davis, I. D.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : E65 - E65
  • [4] EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma
    Davis, I. D.
    Long, A.
    Yip, S.
    Espinoza, D.
    Thompson, J. F.
    Kichenadasse, G.
    Harrison, M.
    Lowenthal, R. M.
    Pavlakis, N.
    Azad, A.
    Kannourakis, G.
    Steer, C.
    Goldstein, D.
    Shapiro, J.
    Harvie, R.
    Jovanovic, L.
    Hudson, A. L.
    Nelson, C. C.
    Stockler, M. R.
    Martin, A.
    ANNALS OF ONCOLOGY, 2015, 26 (06) : 1118 - 1123
  • [5] Circulating biomarkers and outcomes in a single-arm phase II trial of first-line sunitinib alternating with everolimus for advanced renal cell carcinoma (aRCC): EVERSUN ANZUP trial 0901
    Yip, Sonia
    Pavlakis, Nick
    Harvie, Rozelle
    Martin, Andrew
    Jovanovic, Lidija
    Hudson, Amanda
    Thompson, Jennifer F.
    Nelson, Colleen
    Long, Anne
    Steer, Christopher
    Harrison, Michelle L.
    Kannourakis, George
    Goldstein, David
    Kichenadasse, Ganessan
    Lowenthal, Raymond M.
    Stockler, Martin R.
    Davis, Ian D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [6] Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Barrios, Carlos H.
    Kim, Tae Min
    Falcon, Silvia
    Cosgriff, Thomas
    Harker, W. Graydon
    Srimuninnimit, Vichien
    Pittman, Ken
    Sabbatini, Roberto
    Rha, Sun Young
    Flaig, Thomas W.
    Page, Ray
    Bavbek, Sevil
    Beck, J. Thaddeus
    Patel, Poulam
    Cheung, Foon-yiu
    Yadav, Sunil
    Schiff, Edward M.
    Wang, Xufang
    Niolat, Julie
    Sellami, Dalila
    Anak, Oezlem
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2766 - +
  • [7] Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma
    Hsieh, James J.
    Chen, David
    Wang, Patricia I.
    Marker, Mahtab
    Redzematovic, Almedina
    Chen, Ying-Bei
    Selcuklu, S. Duygu
    Weinhold, Nils
    Bouvier, Nancy
    Huberman, Kety H.
    Bhanot, Umesh
    Chevinsky, Michael S.
    Patel, Parul
    Pinciroli, Patrizia
    Won, Helen H.
    You, Daoqi
    Viale, Agnes
    Lee, William
    Hakimi, A. Ari
    Berger, Michael F.
    Socci, Nicholas D.
    Cheng, Emily H.
    Knox, Jennifer
    Voss, Martin H.
    Voi, Maurizio
    Motzer, Robert J.
    EUROPEAN UROLOGY, 2017, 71 (03) : 405 - 414
  • [8] Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
    Motzer, Robert J.
    Hutson, Thomas E.
    Olsen, Mark R.
    Hudes, Gary R.
    Burke, John M.
    Edenfield, William J.
    Wilding, George
    Agarwal, Neeraj
    Thompson, John A.
    Cella, David
    Bello, Akintunde
    Korytowsky, Beata
    Yuan, Jinyu
    Valota, Olga
    Martell, Bridget
    Hariharan, Subramanian
    Figlin, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (12) : 1371 - 1377
  • [9] The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial
    Bjarnason, Georg A.
    Knox, Jennifer J.
    Kollmannsberger, Christian K.
    Soulieres, Denis
    Ernst, D. Scott
    Zalewski, Pawel
    Canil, Christina M.
    Winquist, Eric
    Hotte, Sebastien J.
    North, Scott A.
    Heng, Daniel Yick Chin
    Macfarlane, Robyn Jane
    Venner, Peter M.
    Kapoor, Anil
    Hansen, Aaron R.
    Eigl, Bernhard J.
    Czaykowski, Piotr
    Boyd, Ben
    Wang, Lisa
    Basappa, Naveen S.
    EUROPEAN JOURNAL OF CANCER, 2019, 108 : 69 - 77
  • [10] Re: Randomized Phase II Trial of Sunitinib on an Intermittent versus Continuous Dosing Schedule as First-Line Therapy for Advanced Renal Cell Carcinoma Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2012, 188 (02): : 413 - 414
12345